ECTRIMS

Nancy Chiaravalloti, PhD, shares how cognitive function impacts patients with progressive multiple sclerosis at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Don Mahad, MD, PhD, discusses his research's focus of protecting nerve cells at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Alasdair Coles, MD, University of Cambridge, shares his thoughts on the efficacy of alemtuzumab for patients with multiple sclerosis (MS) at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Assessment of long-term data on treatment utility demonstrates the effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate for multiple sclerosis.

Treatment with Sativex oromucosal spray produces significant reductions in spasticity in patients with multiple sclerosis (MS) compared with placebo, but researchers reported no significant difference between the two in neurophysiologic measures.

Results from the RADIANCE study show that treatment with the selective S1P1 receptor modulator RPC1063 is associated with significant reductions in GD-enhancing lesions on MRI, as well as new or enlarging T2 lesions, compared with placebo.

Patients treated for two years with a combination of glatiramer acetate and estriol experienced a one-third reduction in relapse rate compared with patients who received glatiramer acetate and placebo.

Patients with multiple sclerosis who received thrice-weekly injections of glatiramer acetate 40 mg/ml reported increased satisfaction with their treatment and experienced lower rates of moderate and severe injections site reactions and other adverse events.

Five-year data from the ENDORSE study shows that patients with multiple sclerosis who continued treatment, or who switched from another medication, experienced improved NEDA outcomes.

Mikkel Anthonisan, MD, highlights his experience as the founder of Oceans of Hope, a global voyage to change the perception of multiple sclerosis, at the 2014 Joint ACTRIMS-ECTRIMS Meeting.

Treatment with alemtuzumab was associated with reduced relapse rates and improved MRI outcomes compared to treatment with subcutaneous interferon beta-1a.

Novel drug shown to be more effective than interferon beta-1a in the treatment of multiple sclerosis, but concerns remain over hepatotoxicity, cutaneous reactions, and other adverse events associated with treatment.

A series of nurse-led interventions and patient education, along with titrated drug initiation, were the key components of a successful initiation protocol for patients with multiple sclerosis starting therapy on dimethyl fumarate. The new protocol resulted in fewer discontinuations than the standard initiation protocol.

A version of injectable interferon that multiple sclerosis patients can use far less frequently than existing products is proving safe and effective in clinical trials, its manufacturer says. Biogen Idec announced that new data from the second year of its Phase III clinical trial of peginterferon beta-1a (Plegridy) show it is well tolerated and appears to halt symptoms of relapsing forms of MS. Patients getting the drug had a lower risk of relapse, less disability progression, and fewer new brain lesions than those who got a placebo.

Researchers suggest that monitoring for the loss of CD62L expression on CD4+ T cells is a biomarker for risk assessment in patients treated with natalizumab who may develop PML, since other treatments do not show this pattern of C62L loss of expression.

Late-breaking study results reported at ECTRIMS 2013 indicate that neurofilament levels may be reliable biomarkers of nerve damage and disease progression in patients with relapsing multiple sclerosis.

Study results show that treatment with riluzole did not slow the rate of brain atrophy and did not demonstrate a detectable neuroprotective effect in patients with early RRMS.

Patients treated with oromucosal nabiximols spray experienced up to 30% reduction in spasticity, as measured by a numerical rating scale, after 12 months of treatment.

Nonadherence is highest in patients undergoing treatment with subcutaneous or intramuscular injection formulations of DMT.

Clinicians can use the MSPT, an iPad-based neurological performance test that simulates and extends the Multiple Sclerosis Functional Composite, to measure motor and visual function in patients with multiple sclerosis.

Patients with relapsing-remitting multiple sclerosis treated for two years with alemtuzumab demonstrated improved disease-related disability scores compared to patients who received treatment with subcutaneous interferon beta-1a.

Study results show that hip flexion weakness and, to a lesser extent, ankle dorsiflexion weakness have the greatest impact upon changes in walking speed as MS progresses

Data indicate patients with relapsing remitting multiple sclerosis (RRMS) treated with BG-12 (dimethyl fumarate) showed no clinical disease activity for up to two years.